Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345126 | 1.00 | NPC1 (0.48) | NPC1NAAACA12CA1CA2 | |
| SCHEMBL1444884 | 0.98 | NPC1 (0.45) | NPC1NAAACA12CA1CA2 | |
| SCHEMBL1258617 | 0.93 | NPC1 (0.47) | NPC1NAAACA12CA1CA2 | |
| SCHEMBL1901243 | 0.91 | NPC1 (0.45) | NPC1NAAAEPHX1 | |
| SCHEMBL8614030 | 0.91 | NPC1 (0.45) | NPC1NAAAEPHX1 | |
| SCHEMBL3752919 | 0.91 | NPC1 (0.43) | NPC1NAAAEPHX1 | |
| SCHEMBL470896 | 0.87 | — | — | |
| SCHEMBL10684690 | 0.87 | NPC1 (0.33) | NPC1 | |
| SCHEMBL8133074 | 0.87 | NAAA (0.40) | NPC1NAAACA1CA2EPHX1 | |
| SCHEMBL22124333 | 0.86 | NPC1 (0.39) | NPC1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4654920-A1 | OPHTHALMIC DEVICES HAVING A HIGH REFRACTIVE INDEX AND ABBE NUMBER | Bausch + Lomb Ireland Limited (IE) | 2025-12-03 | — | — | EP | disclosed |
| US-20240277895-A1 | OPHTHALMIC DEVICES HAVING A HIGH REFRACTIVE INDEX AND ABBE NUMBER | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-08-22 | — | — | US | disclosed |
| WO-2024156667-A1 | OPHTHALMIC DEVICES HAVING A HIGH REFRACTIVE INDEX AND ABBE NUMBER | BAUSCH + LOMB IRELAND LIMITED (IE) | 2024-08-02 | — | — | WO | disclosed |
| CN-106715374-B | Polyether diol and process for producing the same | 三菱瓦斯化学株式会社 | 2021-01-12 | — | — | CN | disclosed |
| EP-2464623-B1 | THE RING OPENING OF LACTONES AND LACTAMS | NOVARTIS AG (CH) | 2020-11-04 | — | — | EP | disclosed |
| US-9828338-B2 | Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-10 | — | — | US | disclosed |
| WO-2014144836-A2 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8779198-B2 | Ring opening of lactones and lactams | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| EP-1689702-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| US-5614550-A | ANTICHOLESTEROL AGENTS OR ARTERIOSCLEROSIS AGENTS FOR HUMANS | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| US-5534529-A | Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-09 | — | — | US | disclosed |
| EP-0678503-A1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| CN-1100712-A | Propylene glycol cyclohexyl ether derivatives, method of producing same and uses thereof | ASAHI CHEMICAL IND (JP) | 1995-03-29 | — | — | CN | disclosed |
| EP-0632036-A2 | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1995-01-04 | — | — | EP | disclosed |
| US-5262418-A | Laxatives, gastrointestinal disorders | TANSSEN PHARMACEUTICA N.V. (BE) | 1993-11-16 | — | — | US | disclosed |
| US-5185335-A | Administer to mammals to stimulate gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-02-09 | — | — | US | disclosed |
| EP-0445862-A2 | N-(4-piperidinyl)(dihydrobenzofuran or dihydro-2H-benzopyran)carboxamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-09-11 | — | — | EP | disclosed |
| US-4767883-A | PHOTORESISTS; FLEXIBILITY; LOW VISCOSITY, HIGH GLASS TRANSITION TEMPERATURE; CROSSLINKABLE | EASTMAN KODAK COMPANY (US) | 1988-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | NAAA, FAAH, FAAH2 | NPC1 403/4885NAAA 1/4885CA12 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.